James Heltzer, MD
Ophthalmology · Bethesda, MDNPI 1336171248
Payments from drug & device makers
Across 158 payments — averaging $31.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Alcon$508
- NEW World Medical,inc.$427
- Sight Sciences, Inc.$344
- Sun Pharmaceutical Industries Inc.$252
- Glaukos Corporation$246
- plus $2K from 22 others
What the payments were for
- Travel & lodging$100%
- Food & beverage$5,00899%
- Education$110%
- Gifts$190%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 43 | $1,052 |
| Alcon | 22 | $508 |
| NEW World Medical,inc. | 3 | $427 |
| Sight Sciences, Inc. | 10 | $344 |
| Sun Pharmaceutical Industries Inc. | 8 | $252 |
| Glaukos Corporation | 5 | $246 |
| Aerie Pharmaceuticals, Inc. | 8 | $245 |
| Ivantis, Inc | 3 | $245 |
| Oyster Point Pharma, Inc. | 9 | $242 |
| Bausch & Lomb Americas Inc. | 6 | $224 |
| Biotissue Holdings Inc. | 4 | $220 |
| Novartis | 8 | $178 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 7 | $129 |
| Shire North American Group Inc | 1 | $123 |
| Apellis Pharmaceuticals, Inc. | 1 | $119 |
| Rxsight Inc | 2 | $70 |
| Harrow Eye, LLC | 3 | $65 |
| Tarsus Pharmaceuticals, Inc. | 2 | $61 |
| Kala Pharmaceuticals, Inc. | 3 | $58 |
| Dompe US, Inc. | 2 | $55 |
| Regeneron Healthcare Solutions, Inc. | 1 | $37 |
| Amgen | 1 | $32 |
| ANI Pharmaceuticals, Inc. | 1 | $25 |
| Eyepoint US, Inc. | 1 | $21 |
| Astellas Pharma US Inc | 1 | $21 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $19 |
| Thea Pharma Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ahmed Glaucoma Valve$390
- Kahook Dual Blade$390
- Prokera$155
- AmnioGraft$155
- Hydrus$149
- IC-8 Apthera IOL$123
- enVista MX60 IOL$123
- OMNI$123
- XIIDRA$123
- Syfovre$119
- LUMIGAN$117
- Rocklatan$116
- Rhopressa$116
- CEQUA$116
How this compares
$5,049 in reported general payments places this provider in the 75th percentile of 493 ophthalmology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 73 | $103,807 |
| LumiganBimatoprost | 106 | $71,836 |
| RocklatanNetarsudil Mesylat/Latanoprost | 66 | $56,100 |
| CombiganBrimonidine Tartrate/Timolol | 71 | $29,436 |
| VyzultaLatanoprostene Bunod | 41 | $24,375 |
| RhopressaNetarsudil Mesylate | 36 | $22,489 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 106 | $21,868 |
| MieboPerfluorohexyloctane/Pf | 18 | $19,846 |
| Brinzolamide | 60 | $16,638 |
| CequaCyclosporine | 13 | $16,403 |
| Travoprost | 78 | $15,072 |
| Alphagan PBrimonidine Tartrate | 34 | $14,247 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 44 | $12,882 |
| Brimonidine Tartrate | 200 | $10,316 |
| Latanoprost | 642 | $9,089 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan, Alphagan P | $1,052 | $219,326284 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $245 | $78,589102 claims |
| Bausch & Lomb Americas Inc.Vyzulta, Miebo | $224 | $44,22159 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $252 | $16,40313 claims |
| AlconSimbrinza | $508 | $12,88244 claims |
| NovartisTravatan Z | $178 | $8,37514 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $129 | $3,05712 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 493 ophthalmology providers in Maryland.
Other ophthalmology in Bethesda
- Hatice SenBethesda$225K
- Wai WongBethesda$176K
- Frederick FerrisBethesda$72K
- Allen HuHagerstown$47.9M
- David WarrowHagerstown$10M
- Daniel FinkelsteinBaltimore$6.9M
- Eric SuanBaltimore$6.9M
- Peter CampochiaroBaltimore$5.4M
- Neil BresslerBaltimore$3.6M
- Alfred SommerBaltimore$2.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.